NCT01479972View on ClinicalTrials.gov

Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Tuberculosis

Interventions

BIOLOGICAL

VPM1002

Tuberculosis vaccine

BIOLOGICAL

BCG

commercially available live vaccine BCG

Trial Locations (1)

Unknown

Children's Infectious Diseases Clinical Research Unit, Tygerberg Hospital, Cape Town

All Listed Sponsors

collaborator

Children's Infectious Diseases Clinical Research Unit (KID-CRU), South Africa

UNKNOWN

collaborator

Triclinium Johannesburg, South Africa

UNKNOWN

collaborator

University of Stellenbosch

OTHER

collaborator

HJ-CTC George, South Africa

UNKNOWN

lead

Serum Life Science Europe GmbH

INDUSTRY

NCT01479972 - Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa | Biotech Hunter | Biotech Hunter